Here, we provide the first evidence for an involvement of the mTOR/PI3K pathway in RTK trafficking and expression, thus enforcing the proof of concept that mTOR complexes may be further considered as potential tools for pharmacological interventions in cancer, including GBM [36,52]. The gene discussed is MTOR; the disease is glioblastoma.